Blog

  • Gemini tops the App Store thanks to new AI image model, Nano Banana

    Gemini tops the App Store thanks to new AI image model, Nano Banana

    Gemini’s mobile adoption has been soaring since the August launch of its Nano Banana image editor model, which has received positive reviews, particularly from users who say they can now more easily perform complex edits and create realistic images. The app has climbed to the top of global app stores’ charts and has seen a 45% month-over-month increase in downloads in the month of September so far, according to new data provided by app intelligence firm Appfigures.

    Though the month is only half over, Gemini’s app has already gained 12.6 million downloads in September, up from 8.7 million in August.

    Before this month, Gemini had only gotten as high as No. 3 on the U.S. App Store on January 28, 2025.

    Shortly after Nano Banana’s release, Gemini reached the No. 2 spot on the U.S. App Store on September 8. It then became the No. 1 app on September 12, where it has remained, after knocking OpenAI’s ChatGPT down to No. 2. No other dedicated AI apps are in the top 10 on the App Store at this time.

    Gemini also became one of the top five iPhone apps overall in 108 countries globally, Appfigures’ data indicates.

    On Google Play, Gemini jumped from the No. 26 overall top app in the U.S. on September 8 to become the No. 2 app as of Monday. However, despite Android being Google’s own platform, ChatGPT remains in the top spot as of the time of writing.

    Google has been touting Gemini’s growth, as more mainstream users have been trying out the new image editing features. For instance, Google Gemini and Google Labs VP Josh Woodward shared on X on September 8 that the app had gained 23 million first-time users since the Nano Banana model launched, and those users had shared over 500 million images.

    The app’s rapid growth is also driving increases in consumer spending.

    Of the $6.3 million Gemini generated this year on iOS devices, $1.6 million was from the month of August, with much of that coming in after the Nano Banana model’s release. That’s up 1,291% from January’s figure of $115,000, Appfigures estimates.

    The app is also on track to at least match August’s number if not surpass it in September, as Gemini has pulled in $792,000 so far this month — roughly half of August’s total.

    This year, Gemini’s app has been downloaded 103.7 million times, and has seen 185.4 million downloads to date since its launch on Android in February 2024 and its expansion to iOS later that year.

    Continue Reading

  • Gemini overtakes ChatGPT on App Store, as its Nano Banana AI model drives downloads up 45%

    Gemini overtakes ChatGPT on App Store, as its Nano Banana AI model drives downloads up 45%

    Gemini’s mobile adoption has been soaring since the August launch of its Nano Banana image editor model, which has received positive reviews, particularly from users who say they can now more easily perform complex edits and create realistic images. The app has climbed to the top of global app stores’ charts and has seen a 45% month-over-month increase in downloads in the month of September so far, according to new data provided by app intelligence firm Appfigures.

    Though the month is only half over, Gemini’s app has already gained 12.6 million downloads in September, up from 8.7 million in August.

    Before this month, Gemini had only gotten as high as No. 3 on the U.S. App Store on January 28, 2025.

    Shortly after Nano Banana’s release, Gemini reached the No. 2 spot on the U.S. App Store on September 8. It then became the No. 1 app on September 12, where it has remained, after knocking OpenAI’s ChatGPT down to No. 2. No other dedicated AI apps are in the top 10 on the App Store at this time.

    Gemini also became one of the top five iPhone apps overall in 108 countries globally, Appfigures’ data indicates.

    On Google Play, Gemini jumped from the No. 26 overall top app in the U.S. on September 8 to become the No. 2 app as of Monday. However, despite Android being Google’s own platform, ChatGPT remains in the top spot as of the time of writing.

    Google has been touting Gemini’s growth, as more mainstream users have been trying out the new image editing features. For instance, Google Gemini and Google Labs VP Josh Woodward shared on X on September 8 that the app had gained 23 million first-time users since the Nano Banana model launched, and those users had shared over 500 million images.

    The app’s rapid growth is also driving increases in consumer spending.

    Of the $6.3 million Gemini generated this year on iOS devices, $1.6 million was from the month of August, with much of that coming in after the Nano Banana model’s release. That’s up 1,291% from January’s figure of $115,000, Appfigures estimates.

    The app is also on track to at least match August’s number if not surpass it in September, as Gemini has pulled in $792,000 so far this month — roughly half of August’s total.

    This year, Gemini’s app has been downloaded 103.7 million times, and has seen 185.4 million downloads to date since its launch on Android in February 2024 and its expansion to iOS later that year.

    Continue Reading

  • Colgate Agrees To Show Safe Toothpaste Amounts For Kids After Legal Pressure – Colgate-Palmolive (NYSE:CL)

    Colgate Agrees To Show Safe Toothpaste Amounts For Kids After Legal Pressure – Colgate-Palmolive (NYSE:CL)

    Attorney General Ken Paxton has reached an agreement with Colgate-Palmolive Company CL, addressing concerns over misleading toothpaste packaging and advertising aimed at children.

    The agreement announced on Monday requires the company to update its marketing for fluoride toothpaste products intended for kids under six, ensuring that images on packaging and promotions show only a “pea-sized” amount of toothpaste.

    The investigation began after Paxton raised concerns that toothpaste brands were depicting excessive amounts of toothpaste. He argues that the imagery potentially encourages unsafe use among young children.

    Colgate subsequently agreed to change its packaging and marketing for its Colgate, Tom’s of Maine, and hello brands.

    These changes will be implemented wherever images of toothpaste on a toothbrush are shown.

    Also Read: Colgate-Palmolive’s Outlook Remains Cautious As Restructuring Plans Take Shape

    The written instructions on Colgate’s product labels, which align with FDA guidelines, will remain unchanged. However, starting Nov. 1, the new visual guidelines will be rolled out online first, followed by updates to physical packaging.

    These revisions will reflect age-appropriate toothpaste amounts that are consistent with safety recommendations.

    In May, Paxton issued Civil Investigative Demands (CIDs) to Colgate-Palmolive and Procter & Gamble Co PG—the maker of Crest fluoride toothpaste—over allegedly misleading and unsafe marketing of their toothpaste products to parents and children.

    The probe follows increasing scientific evidence that excessive fluoride exposure may harm children’s health. Notably, an August 2024 meta-analysis by the National Toxicology Program linked fluoride exposure to lower IQ levels in children.

    Price Action: CL stock is down 0.73% at $81.53 at the last check on Tuesday.

    Read Next:

    Image: Shutterstock

    Stock Score Locked: Want to See it?

    Benzinga Rankings give you vital metrics on any stock – anytime.

    Reveal Full Score

    Market News and Data brought to you by Benzinga APIs

    © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Continue Reading

  • T-DXd Shows Real-World Efficacy in HER2+ and HER2-Low/Zero Breast Cancer Brain Metastases

    T-DXd Shows Real-World Efficacy in HER2+ and HER2-Low/Zero Breast Cancer Brain Metastases

    Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) demonstrated durable systemic and intracranial activity in patients with breast cancer brain metastases (BCBM), including those with HER2-positive, HER2-low, and HER2-zero disease, according to findings from a retrospective real-world analysis.1

    At a median follow-up of 13 months (95% CI, 9.1-16.9), patients with HER2-positive disease (n = 58) achieved a median progression-free survival (PFS) of 11.0 months (95% CI, 7.0-14.9) and a median overall survival (OS) of 46.0 months (95% CI, 21.8-70.2). The 12-month PFS and OS rates were 42.9% (95% CI, 29.4%-62.7%) and 88.7% (95% CI, 79.7%-98.8%), respectively. The median intracranial PFS (IC-PFS) was 13.0 months (95% CI, 10.0%-16.0%), and the 12-month IC-PFS rate was 52.6% (95% CI, 38.2%-72.3%).

    At a median follow-up of 10 months (95% CI, 4.5-15.5) in the HER2-low/zero cohort (n = 30), the median PFS and OS were 4.0 months (95% CI, 2.5-5.5) and 26.0 months (95% CI, 13.7-not evaluable), respectively. The respective 12-month PFS and OS rates were 26.0% (95% CI, 12.9%-52.3%) and 55.6% (95% CI, 39.5%-78.2%). The median CNS PFS was 5 months (95% CI, 3.2–6.8), and the 12-month IC-PFS rate was 44.6 (95% CI, 26.4%-75.4%)

    “The present study showed a substantial and durable intracranial efficacy of T-DXd in breast cancer brain metastases with both HER2-positive and low/zero expression, stable and active disease, and patients with significant symptoms and leptomeningeal disease, thus providing valuable insights for routine practice,” lead study author Qingru Zhou, MD, of the Department of Medical Oncology at Sun Yat-Sen University Cancer Center in Guangzhou, China, and colleagues wrote in a publication of the data.

    Real-World Study Design and Enrollment Criteria

    In the United States, T-DXd has been approved by the FDA in the following breast cancer indications:2

    • For adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+ or in situ hybridization [ISH]+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
    • For adult patients with unresectable or metastatic hormone receptor (HR)–positive, HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
    • For adult patients with HER2-low (IHC 1+ or IHC 2+/ISH–) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

    This multicenter, retrospective, real-world study was conducted to evaluate the efficacy and safety of T-DXd in patients with breast cancer brain metastases, including those with HER2-positive, HER2-low, and HER2-zero disease, as well as patients with stable or active brain metastases, neurological symptoms, or leptomeningeal disease.1 Eligible patients were treated between January 2020 and July 2024.

    Inclusion criteria required patients to have histologically confirmed breast cancer; brain metastases confirmed by MRI; and either HER2-positive disease (IHC 3+ or IHC 2+/ISH+) or HER2-low/zero disease (IHC 0, 1+, or 2+/ISH–). Patients needed to receive at least one cycle of T-DXd, either as monotherapy or in combination with other agents, and have available clinical data.

    Data were collected retrospectively from hospital information systems, including demographics, clinical symptoms, tumor characteristics, prior therapies, laboratory testing, and imaging studies. Patients with active brain metastases were defined as those with newly diagnosed, untreated brain metastases or central nervous system disease progression following local or systemic therapy.

    The primary efficacy end points included PFS, IC-PFS, OS, objective response rate (ORR), disease control rate (DCR), and intracranial ORR (IC-ORR).

    Additional Data

    Among evaluable patients with HER2-positive disease (n = 46), the confirmed ORR was 65.2% (95% CI, 49.7%-78.2%), and the disease control rate (DCR) was 91.3% (95% CI, 78.3%-97.2%); complete response (CR) was observed in 6.7% of patients. The IC-ORR and IC-DCR were 61.0% (95% CI, 44.5%-75.4%) and 90.2% (95% CI, 75.9%-96.8%) per RECIST 1.1 criteria, respectively; these respective rates were 59.5% (95% CI, 43.4%-74.0%) and 88.1% (95% CI, 73.6%-95.5%) by RANO-BM criteria.

    For patients with HER2-low/zero disease evaluable for response (overall, n = 21; intracranial, n = 18), the ORR was 33.3% (95% CI, 15.5%-56.9%), and the DCR was 66.7% (95% CI, 43.1%-84.5%), with no CRs observed. The IC-ORR was 44.4% (95% CI, 22.4%-68.7%), and the IC-DCR was 88.9% (95% CI, 64.0%-98.1%) by both RECIST 1.1 and RANO-BM criteria. Notably, among 3 patients with HER2-zero disease, 1 achieved a partial response, 1 achieved stable disease, and 1 patient experienced progressive intracranial disease.

    HR status further influenced outcomes within this subgroup. Patients with HR-positive/HER2-low or zero disease (n = 19) had longer PFS and IC-PFS compared with those with HR-negative/HER2-low or zero disease (n = 11), with a median PFS of 10.0 vs 3.0 months (P < .001). The median IC-PFS was not reached vs 4.0 months, respectively (P = .06).

    LMD Cohort Findings

    In the leptomeningeal disease subgroup (n = 16), efficacy outcomes differed by HER2expression. Among the 10 patients with HER2-positive disease, the median IC-PFS was 16.0 months (95% CI, 8.4-23.7), with a 12-month IC-PFS rate of 72.0% (95% CI, 44.4%-100%). In contrast, the 6 patients with HER2-low/zero disease had a median IC-PFS of 5 months (95% CI, 3.4-6.6), and a 12-month IC-PFS rate of 27.8% (95% CI, 5.4-%-100%). One patient with HR-negative/HER2-low disease experienced a PFS of 4 months. Median OS had not been reached for either HER2-positive or HER2-low/zero subgroups at the time of data cutoff.

    Additionally, 7 of the 16 patients in this subgroup received T-DXd in combination with bevacizumab (Avastin). However, no statistically significant improvement in IC-PFS was observed with combination therapy compared with T-DXd monotherapy (P = .58).

    Safety Findings

    In this real-world cohort, treatment discontinuation due to adverse effects (AEs) occurred in 7 patients (8.0%), with financial toxicity representing the leading cause (n = 4; 4.6%). The most frequently reported treatment-emergent AEs (TEAEs) were fatigue (45.9%), loss of appetite (25.2%), and nausea (11.4%).

    Grade 3 or higher TEAEs were primarily hematologic, including neutropenia in 6 patients (6.9%) and thrombocytopenia in 4 patients (4.6%). Interstitial lung disease (ILD) was observed in 7 patients (8.0%); of these, 2 patients (2.3%) experienced grade 3 ILD requiring treatment discontinuation.

    No new safety signals were identified, and the overall safety profile of T-DXd in this real-world population was consistent with prior clinical experience.

    References

    1. Zhou Q, Li Y, He N, et al. Efficacy and safety of T-DXd in HER2-positive and low/zero metastatic breast cancer brain metastases: a retrospective multicenter real-world study. Cancer Sci. Published online September 11, 2025. doi:10.1111/cas.70181
    2. Enhertu. Prescribing information. Daiichi Sankyo. Updated January 2025. Accessed September 15, 2025. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true

    Continue Reading

  • India hammer Maldives to begin their SAFF U17 Championship title defense

    India hammer Maldives to begin their SAFF U17 Championship title defense

    The Blue Colts scored six goals in the opener to register their first three points in the group stage.

    The India U17 men’s national team began their SAFF U17 Championship 2025 title defence in an emphatic fashion as they cruised to a 6-0 demolition of Maldives in their opening Group B encounter at the Racecourse International Stadium in Colombo, Sri Lanka, on Tuesday, September 16, 2025.

    The Blue Colts were clinical and commanding from the first whistle as they sliced through the Maldives defence at will and announced their championship intent with a fluid, attacking performance.

    Dallalmuon Gangte struck twice, while Hrishikesh Charan Manavathi, Kamgouhao Doungel, Wangkheirakpam Gunleiba, and Aazim Parveez Najar joined the scoresheet in what was a complete performance at both ends of the pitch.

    Early assault from India

    The match was barely settling when India seized control. Bibiano Fernandes’ side played with high press and kept possession with confident passing patterns. They also constantly switched flanks to pull the Maldives defence out of shape, with Wangkheirakpam Gunleiba in particular proving unplayable on the left wing. His pace and intelligent crossing repeatedly carved open spaces in the final third.

    India took the lead in the 12th minute. Wangkheirakpam darted past his marker, cut inside and whipped in a delightful ball. Manavathi cleverly dummied the cross, deceiving the Maldives goalkeeper completely and leaving Gangte with a simple conversion into an empty net.

    India doubled their advantage in the 29th minute. It was again Wangkheirakpam creating the havoc, blazing down the left and squaring a low ball for Manavathi, who muscled past Ibrahim Avsam Abdulla to steer in the second.

    Maldives offered little in response. Aside from speculative attempts from Aakif Bin Mohammed and Aidh Mohammed Jaweez, the islanders were second best in every department.

    Ruthless Blue Colts

    India hammer Maldives to begin their SAFF U17 Championship title defense.

    The Blue Colts continued their rout in the second half too and extended their lead further in the 49th minute. After being teed up by Denny Singh Wangkhem, Wangkheirakpam provided his third assist of the match with a cross across the face of the Maldives goal and Doungel powered his shot into the roof of the net.

    Wangkheirakpam then crowned his stellar performance with a goal of his own in the 58th minute. After Wangkhem stole the ball high up the pitch, he released Wangkheirakpam, who left his defender in the dust before unleashing a thunderous left-footed strike into the far corner.

    Maldives’ composure disintegrated under constant waves of Indian attacks and, in the 68th minute, the harassed Avsam Abdulla brought down Rahan Ahmed in the box. Gangte stepped up from the spot and confidently slotted home his second of the match, making it 5-0.

    But India weren’t done. With four minutes remaining, Azlaan Shah floated in a teasing cross from the right which substitute Aazim Parveez Najar met with a precise header, rounding off the rout in the 86th minute.

    India U17: Manashjyoti Barua (GK), Maldino Singh Yumnam (Md Aimen Bin ), Shubham Poonia, Konthoujam Korou Meitei (Indra Rana Magar 59′), Thangoumang Touthang, Kamgouhao Doungel (Azlaan Shah Kh 55′), Dallalmuon Gangte, Houlungou Mate, Hrishikesh Charan Manavathi (Rahan Ahmed 55′), Wangkheirakpam Gunleiba (Aazim Parveez Najar 84′), Denny Singh Wangkhem (C)

    When will India play their next game in the SAFF U17 Championship 2025?

    The Blue Colts will face Bhutan next on September 19, 2025.

    For more updates, follow Khel Now on Facebook, Twitter, Instagram, Youtube; download the Khel Now Android App or IOS App and join our community on Whatsapp & Telegram.


    Continue Reading

  • Brain shunt surgery improves walking and quality of life in older adults with hydrocephalus

    Brain shunt surgery improves walking and quality of life in older adults with hydrocephalus

    Implanting a brain shunt in older people diagnosed with idiopathic normal pressure hydrocephalus (iNPH) is effective in improving their symptoms, a randomized, double-blinded, multi-center patient trial shows.

    This condition is associated with an enlargement of the brain’s ventricles, the spaces where fluid to cushion the brain and spine is produced and stored. The disorder is manifested by slow gait and balance issues that increase the risk for falls, as well as difficulty thinking, memory loss, and urinary incontinence.

    “If there’s one thing this study does, it resolves a controversy that’s been around for many, many years,” said Dr. Michael A. Williams, professor of neurology and neurological surgery at the University of Washington School of Medicine in Seattle, and one of the lead authors of the study. The other lead authors are Dr. Mark G. Luciano of Johns Hopkins University, who is the principal investigator for the study, and Dr. Mark G. Hamilton of University of Calgary in Alberta, Canada.

    There’ve been a lot of physicians who doubt that the disorder exists or that treatment with the surgical implantation of a shunt is either effective or safe. Our trial puts that to rest. Our hope is that now, more neurologists, more neurosurgeons, more doctors will entertain the possibility of iNPH as a diagnosis for their patients, take them through appropriate diagnostic steps and treat them when hydrocephalus is found.”


    Dr. Michael A. Williams, professor of neurology and neurological surgery, University of Washington School of Medicine

    The first set of results comparing treatment and placebo groups were published today, Sept. 16, in the New England Journal of Medicine and simultaneously presented at the 150th annual meeting of the American Neurological Association in Baltimore.

    The symptoms are often not attributed to normal pressure hydrocephalus, because such troubles are common in older people and could be due to many other factors. Consequently, the condition is hard to diagnose. However, if hydrocephalus significantly contributes to such symptoms, then treating it can make a big difference in patients’ lives, according to these latest findings.

    The average age of people with the condition is 75 years, and the older the population, the more likely they are to have normal pressure hydrocephalus. It affects about 1.5% of the population of people in their 70’s, and as much as 7% of those in their 80’s. The condition is diagnosed through a series of tests that include symptom evaluation, MRI brain scans, and in-hospital evaluations of response to removing some spinal fluid.

    Williams noted, however, that at best maybe only 5% to 10% of patients diagnosed with normal pressure hydrocephalus get treatment.

    The Placebo-Controlled Efficacy in Idiopathic Normal Pressure Hydrocephalus Shunting (PENS) study participants, all of whom had a confirmed diagnosis, had a shunt surgically placed under general anesthesia.

    The shunt is an internal drainage system. A valve goes under the skin at the side of or back of the head. A small tube from the valve is inserted into a brain ventricle, and a second tube is guided from the valve under the skin to the abdomen, where the excess cerebral fluid can drain.

    The shunt used in the study can be turned on or off, and the flow adjusted, with a magnetic device placed over the valve on the scalp. Half of participants had their shunts turned on, and half had them turned off. Neither the patients nor those evaluating them knew which option they had.

    In comparing the two groups, the researchers found that patients with an open shunt increased their gait velocity by more than 0.2 meter per second or double the minimum clinically meaningful difference of 0.1 meter per second. Moreover, 80% of them passed that threshold. In the group of patients with closed shunts, gait speed did not improve.

    “There was very clearly a difference between the two groups on this measurement,” Williams said. In addition, those with closed shunts reported more falls than did those with open shunts.

    The patients were surveyed about their quality of life and ability to perform everyday activities. Those rose in the treated group and stayed the same or diminished in the placebo group.

    At the conclusion of this portion of the trial, the researchers turned on the placebo group’s shunts. Both groups continue to be evaluated. Additional long-term outcomes from the study are still pending, such as whether the improvements were sustained and whether MRI brain imaging can be correlated with symptom reduction.

    The first phase of the study used only screening methods to check for cognitive impairment. As the study continues, researchers will use more complete assessments with neuropsychology testing. This will provide information on the range of impairments and whether they get better with treatment.

    Dr. Nikolas Dasher, a neuropsychologist in the Department of Rehabilitation Medicine at UW Medicine, played a key role in assessing the efficacy of shunting for this study.

    Twenty-one medical centers participated in the trial. One was in Sweden; the rest were located across the United States and Canada. Ninety-nine participants were enrolled.”If our study has influence, we should see an increase in the number of people who are being found to have iNPH and who are getting treated,” Williams said. “That’s going to be a lot of improvement for the elderly population. There should be some reduction in healthcare costs associated with that as well.”

    The study was supported by the National Institute of Neurological Disorders and Stroke (U01NS122764) and Trial Innovation Network of the National Institutes of Health (U24TR001597 and U24TR004440).

    Source:

    University of Washington School of Medicine/UW Medicine

    Journal reference:

    Luciano, M. G., et al. (2025) A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus. New England Journal of Medicine. doi.org/10.1056/NEJMoa2503109

    Continue Reading

  • BorgWarner Named to the 100 Best Corporate Citizens of 2025

    Auburn Hills, Michigan, September 16, 2025 – BorgWarner has been recognized by 3BL, a leading sustainability communications partner, as one of the 100 Best Corporate Citizens of 2025, marking the third consecutive year the company has been included. This prestigious ranking acknowledges BorgWarner’s exceptional commitment to environmental, social, and governance (ESG) transparency and performance among the largest U.S. public companies. Even as political attitudes toward ESG policies and disclosures shift in the United States, the nation’s largest companies continue to increase their levels of transparency, with average scores up 2.5% from last year.

    The 100 Best Corporate Citizens ranking evaluates Russell 1,000 companies based on 219 factors across seven pillars, including climate change, employee relations, environment, governance, human rights, and stakeholders and society. After integrating dozens of new factors in 2024 to more accurately assess corporate performance as well as disclosure, 3BL limited year-over-year changes to the ranking methodology. 2025 changes include increasing the weight of some performance-based factors introduced in 2024 and ISS Sustainability Solutions’ annual enhancements to the E&S Disclosure QualityScore and Governance QualityScore.

    “It’s been a challenging year for responsible business, but the companies on this list have shown the courage to stay the course,” said Charlie Wilkie, CEO of 3BL. “In a climate where trust is the new KPI, they’re proving that transparency and accountability aren’t just ideals — they’re the foundation of stronger companies. The 100 Best Corporate Citizens exists to spotlight that strength, and to push the standard for corporate leadership higher every year.”

    Unlike other rankings, the 100 Best Corporate Citizens relies solely on publicly available data and information, eliminating the need for questionnaires or company submissions, and there is no fee for companies to be considered. To ensure accuracy, companies have the option to verify the data collected for the ranking at no cost. The data and information used for the 2025 ranking were published between June 2024 and June 2025.

    “BorgWarner is proud to be recognized by 3BL as one of the 100 Best Corporate Citizens for the third consecutive year for our unwavering commitment to transparency of our sustainability goals and performance,” said Joseph Fadool, President and CEO, BorgWarner. “As outlined in our recently published sustainability report, we continue to make meaningful progress toward our goals and remain dedicated to setting a strong example for responsible corporate citizenship.”

    Continue Reading

  • How to watch the Allen Iverson documentary series on Prime Video – About Amazon

    How to watch the Allen Iverson documentary series on Prime Video – About Amazon

    1. How to watch the Allen Iverson documentary series on Prime Video  About Amazon
    2. Allen Iverson Documentary Series Release Date Announced for Prime Video  Bleacher Report
    3. ‘Allen Iv3rson’ Docuseries Sets Premiere Date At Prime Video  Deadline
    4. Prime Video releasing Allen Iverson original series  yahoo.com
    5. Prime Video’s Allen Iverson documentary to premiere Oct. 23  HoopsHype

    Continue Reading

  • Stunning new imagery shows big changes in the 1st black hole ever captured by humanity (photo, video)

    Stunning new imagery shows big changes in the 1st black hole ever captured by humanity (photo, video)

    When you buy through links on our articles, Future and its syndication partners may earn a commission.

    Images of the supermassive black hole at the heart of the galaxy M87 taken by the Event Horizon Telescope, showing the shifting polarization of its magnetic field. | Credit: EHT Collaboration

    The Event Horizon Telescope (EHT) has captured stunning, newly revealed images of the supermassive black hole that lies at the heart of the galaxy M87. The EHT made this black hole, known as M87*, famous in April 2019 when it was revealed as the first black hole ever imaged by humanity.

    These images of M87*, located around 55 million light-years from Earth, show that the polarization of the magnetic fields around the black hole reversed over a period of four years. The new observations of M87* also show the telltale signs of a jet of matter emerging from around the black hole, with its base connected to the bright ring around the outer boundary, or “event horizon,” around M87*.

    The images could help scientists further develop theories of how matter behaves in the extreme environments around supermassive black holes, which have masses of millions or even billions of suns and are found at the hearts of all large galaxies.

    three images of a supermassive black hole, each one showing it as a dark blotch surrounded by an orangish disk

    New images of M87* show the magnetic fields around the black hole swirling one way in 2017 then another in 2021. | Credit: EHT collaboration

    “The fact that the polarization pattern flipped direction from 2017 to 2021 was totally unexpected,” EHT team member Jongho Park, a researcher at Kyunghee University in South Korea, said in a statement. “It challenges our models and shows there’s much we still don’t understand near the event horizon.”

    The observations showed the ring of superheated, highly magnetized gas, or plasma, flowing one way around this 6.5-billion-solar-mass black hole in 2017, then settling in 2018 before reversing and spiraling in the opposite direction in 2021. And, to make matters more intriguing, not everything about the plasma changed between 2017 and 2021.

    “What’s remarkable is that, while the ring size has remained consistent over the years, confirming the black hole’s shadow predicted by Einstein’s theory [of general relativity], the polarization pattern changes significantly,” said team co-leader Paul Tiede, an astronomer at the Center for Astrophysics | Harvard & Smithsonian. “This tells us that the magnetized plasma swirling near the event horizon is far from static; it’s dynamic and complex, pushing our theoretical models to the limit.”

    Matter swirling into the supermassive black hole at the centre of M87.

    The first image of a black hole ever captured by humanity shows a ring of plasma swirling around M87.* | Credit: Event Horizon Telescope

    The changing polarization of plasma around M87* seems to indicate an evolving and turbulent environment around this black hole, which could be impacting how it feeds on surrounding matter. The cause of the reversal isn’t clear yet, but it could be the result of the magnetic structure of the plasma combined with external effects.

    The newly released images also allowed the team to home in on the base of the jet of particles erupting from around M87* at near-light speed with the EHT for the first time. This is an important breakthrough, because jets like this one, which are comprised of particles channeled to the poles of black holes by magnetic fields, are thought to represent one of the ways supermassive black holes sculpt the galaxies in which they sit by pumping vast amounts of energy into their surroundings.

    The new images also illustrate changes that the EHT itself has undergone. The final image, collected in 2021, is sharper due to the addition of two new telescopes, Kitt Peak in Arizona and NOEMA (Northern Extended Millimeter Array) in France, to the 25 Earth- and space-based instruments that make up the EHT network, which boosted the project’s sensitivity.

    “These results show how the EHT is evolving into a fully fledged scientific observatory, capable not only of delivering unprecedented images, but of building a progressive and coherent understanding of black hole physics,” said EHT scientist Mariafelicia De Laurentis, an astronomer at the University of Naples Federico II in Italy. “Each new campaign expands our horizon, from the dynamics of plasma and magnetic fields to the role of black holes in cosmic evolution. It is a concrete demonstration of the extraordinary scientific potential of this instrument.”

    Related Stories:

    — Event Horizon Telescope: A complete guide

    — 1st monster black hole ever pictured erupts with surprise gamma-ray explosion

    — Brightest quasar ever seen is powered by black hole that eats a ‘sun a day’

    Future images from the EHT are set to improve thanks to upgrades to two telescopes in its network, the Greenland Telescope and the James Clerk Maxwell Telescope. Thus, the EHT will continue playing a crucial role in our understanding of black hole physics for years to come, team members said.

    “Year after year, we improve the EHT — with additional telescopes and upgraded instrumentation, new ideas for scientific explorations, and novel algorithms to get more out of the data,” said team co-leader Michael Janssen, of Radboud University in the Netherlands. “For this study, all these factors nicely conspired into new scientific results and new questions, which will certainly keep us busy for many more years.”

    The team’s research was published in the August edition of the journal Astronomy & Astrophysics.

    Continue Reading

  • Soft robotic arms for rapid ER treatment – Politico

    1. Soft robotic arms for rapid ER treatment  Politico
    2. Robotic device could make intubation faster and easier for first responders, small study suggests  statnews.com
    3. Soft robotic intubation tool enables 87% first-pass success for minimally trained users  Interesting Engineering
    4. UCSB-designed soft robot intubation device could save lives  UC Santa Barbara
    5. Soft robot intubation device, designed specifically for non-expert users, could save lives  Medical Xpress

    Continue Reading